introduct
anim
studi
acut
lung
injuri
ali
suggest
nebulis
heparin
may
limit
damag
fibrin
deposit
alveolar
space
microcircul
human
studi
undertaken
date
assess
feasibl
safeti
potenti
anticoagul
effect
administr
nebulis
heparin
patient
ali
method
open
label
phase
trial
four
escal
dose
nebulis
heparin
perform
total
ventil
patient
ali
studi
first
group
administ
total
uday
second
group
uday
third
group
uday
fourth
group
u
day
assess
lung
function
includ
pao
fio
ratio
lung
complianc
alveolar
dead
space
fraction
monitor
anticoagul
includ
activ
partial
thromboplastin
time
aptt
thrombin
clot
time
bronchoalveolar
lavag
fluid
collect
prothrombin
fragment
tissu
plasminogen
activ
level
assess
analysi
varianc
use
compar
effect
dose
seriou
advers
event
occur
dose
chang
time
pao
fio
ratio
lung
complianc
alveolar
dead
space
fraction
level
similar
dose
trend
increas
aptt
thrombin
clot
time
level
present
higher
dose
p
p
respect
highest
dose
aptt
reach
second
follow
cessat
nebulis
heparin
aptt
fell
second
p
bronchoalveolar
lavag
sampl
trend
reduc
prothrombin
fragment
level
present
higher
dose
p
tissu
plasminogen
activ
level
similar
dose
conclus
administr
nebulis
heparin
mechan
ventil
patient
ali
feasibl
nebulis
heparin
associ
seriou
advers
event
higher
dose
increas
aptt
level
larger
trial
requir
investig
safeti
efficaci
nebulis
heparin
trial
due
consider
must
given
system
anticoagul
effect
trial
registr
australian
clinic
trial
registri
administr
nebulis
heparin
mechan
ventil
patient
ali
feasibl
associ
seriou
advers
event
higher
dose
nebulis
heparin
increas
aptt
level
larger
trial
requir
investig
safeti
efficaci
nebulis
heparin
ali
acut
lung
injuri
ali
seriou
clinic
problem
estim
case
ali
develop
unit
state
year
associ
death
million
hospit
day
mortal
ali
current
method
prevent
treat
ali
ali
characteris
rapid
onset
respiratori
distress
set
inflammatori
insult
lung
inflammatori
insult
includ
sepsi
trauma
hypotens
cardiopulmonari
bypass
pancreat
aspir
multipl
transfus
septic
insult
commonest
caus
ali
pneumonia
trigger
case
sepsi
elsewher
bodi
caus
case
one
mechan
inflamm
caus
ali
deposit
fibrin
alveolar
space
microcircul
fibrin
deposit
alveolar
sac
give
rise
hyalin
membran
deposit
microvasculatur
result
thrombosi
nebulis
heparin
may
limit
fibrin
deposit
alveolar
space
microcircul
heparin
anticoagul
fibrinolyt
action
studi
anim
model
ali
demonstr
nebulis
heparin
improv
pao
fio
ratio
reduc
histolog
ali
acut
lung
injuri
aptt
activ
partial
thromboplastin
time
bal
bronchoalveolar
lavag
elisa
enzymelink
immunosorb
assay
pao
fio
arteri
oxygen
partial
pressur
inspir
oxygen
fraction
ratio
ptf
prothrombin
fragment
tct
thrombin
clot
time
tpa
tissu
plasminogen
activ
page
number
citat
purpos
damag
addit
set
lung
injuri
trigger
cardiac
surgeri
preoper
heparin
infus
reduc
evid
pulmonari
microvascular
thrombosi
unawar
previou
trial
nebulis
heparin
patient
ali
therefor
undertook
present
trial
assess
feasibl
safeti
potenti
anticoagul
effect
nebulis
heparin
mechan
ventil
patient
ali
addit
assess
effect
intrapulmonari
coagul
activ
fibrinolysi
studi
approv
st
vincent
hospit
human
research
ethic
committe
consent
obtain
patient
next
kin
particip
studi
present
studi
openlabel
escalatingdosag
phase
trial
nebulis
heparin
heparin
sodium
u
ml
cp
pharmaceut
ltd
wrexham
uk
mechan
ventil
patient
ali
four
dose
studi
dose
assess
four
patient
day
first
group
administ
uday
u
hourli
four
nebulis
second
group
receiv
u
day
u
hourli
four
nebulis
third
group
receiv
uday
u
hourli
four
nebulis
fourth
group
administ
uday
u
hourli
eight
nebulis
final
nebulis
heparin
administ
hour
baselin
uday
uday
uday
group
hour
uday
group
studi
patient
admit
intens
care
unit
met
follow
inclus
exclus
criteria
inclus
criterion
initi
mechan
ventil
acut
respiratori
dysfunct
characteris
pao
fio
ratio
mmhg
acut
respiratori
dysfunct
primarili
due
direct
indirect
inflammatori
insult
lung
exclus
criteria
hour
sinc
inclus
criterion
met
hypoxemia
predominantli
due
caus
ali
congest
heart
failur
pulmonari
embol
chronic
obstruct
airway
diseas
asthma
system
anticoagul
includ
activ
protein
c
potenti
need
haemofiltr
therefor
anticoagul
pulmonari
haemorrhag
previou
month
uncontrol
bleed
signific
bleed
disord
allergi
heparin
includ
heparininduc
thrombocytopenia
age
year
year
patient
unlik
surviv
hour
bronchoscopi
possibl
due
sever
hypoxia
previou
intub
ventil
current
admiss
noninvas
ventil
hour
prior
intub
pregnanc
heparin
nebulis
aeroneb
pro
nebul
aerogen
ltd
galway
ireland
minut
nebulis
place
inspiratori
line
cm
circuit
heat
moistur
exchang
remov
nebulis
patient
ventil
pressuresupport
mode
ventil
upper
pressur
level
maintain
cmh
p
f
ratio
lung
complianc
alveolar
dead
space
fraction
measur
baselin
hour
measur
alveolar
dead
space
fraction
previou
studi
suggest
variabl
may
reflect
extent
microvascular
thrombosi
ali
evid
blood
stain
respiratori
secret
assess
bedsid
nurs
follow
routin
pulmonari
suction
activ
partial
thromboplastin
time
aptt
thrombin
clot
time
tct
assess
time
point
lung
function
hour
uday
group
prothrombin
fragment
ptf
tissu
plasminogen
activ
tpa
level
bronchoalveolar
lavag
bal
fluid
assess
baselin
follow
final
nebulis
bal
undertaken
averag
hour
follow
final
nebulis
standard
formula
use
calcul
lung
complianc
alveolar
dead
space
fraction
measur
cosmo
plu
respiron
monitor
novametrix
medic
system
wallingford
ct
usa
bronchoscop
wedg
distal
airway
initi
ml
warm
salin
inject
discard
five
ml
aliquot
instil
aspir
portion
aspir
fluid
spun
g
minut
supernat
store
sampl
assay
elisa
ptf
level
enzygnost
monoclon
assay
behr
marburg
germani
tpa
antigen
level
tintel
tpa
biopool
intern
ventura
ca
usa
base
previou
studi
determin
four
patient
group
would
adequ
detect
major
anticoagul
effect
analysi
varianc
use
compar
effect
heparin
dose
p
f
ratio
lung
complianc
alveolar
dead
space
fraction
aptt
tct
intrapulmonari
ptf
tpa
level
fisher
exact
test
compar
categor
variabl
student
test
compar
normal
distribut
variabl
data
report
mean
standard
deviat
statist
analysi
perform
jmp
program
sa
institut
inc
cari
nc
usa
sixteen
patient
enrol
mean
patient
age
year
acut
physiolog
chronic
health
evalu
score
ii
baselin
p
f
ratio
mmhg
lung
complianc
ml
cmh
alveolar
dead
space
fraction
prophylact
subcutan
heparin
administ
patient
studi
commonest
aetiolog
factor
ali
pneumonia
tabl
time
intub
initi
heparin
nebulis
hour
mean
mechan
ventil
time
day
intens
care
length
stay
day
hospit
length
stay
day
tracheostomi
rate
hospit
mortal
chang
time
p
f
ratio
lung
complianc
alveolar
dead
space
fraction
similar
dose
studi
statist
signific
differ
found
dosag
interact
dosag
time
figur
one
patient
uday
group
develop
bloodstain
respiratori
secret
seventh
dose
associ
deterior
lung
function
blood
stain
resolv
follow
withdraw
nebulis
heparin
mean
aptt
group
follow
final
nebulis
order
increas
dose
second
normal
rang
second
second
second
second
p
analysi
varianc
comparison
dose
figur
mean
tct
group
follow
final
nebulis
order
increas
dose
second
normal
rang
second
second
second
second
p
analysi
varianc
comparison
dose
figur
higher
dose
group
aptt
tct
fell
follow
cessat
nebulis
heparin
highest
dose
aptt
fell
second
second
p
figur
ptf
level
bal
fluid
uday
group
higher
follow
final
nebulis
u
day
uday
uday
group
ptf
level
remain
similar
baselin
level
follow
final
nebulis
p
analysi
varianc
comparison
dose
figur
tpa
level
similar
baselin
level
dose
follow
final
nebulis
figur
chang
arteri
inspir
oxygen
ratio
nebulis
heparin
dosag
chang
arteri
inspir
oxygen
ratio
nebulis
heparin
dosag
percentag
chang
baselin
arteri
inspir
oxygen
ratio
p
f
mean
standard
deviat
chang
lung
complianc
nebulis
heparin
dosag
chang
lung
complianc
nebulis
heparin
dosag
percentag
chang
baselin
lung
complianc
time
dose
mean
standard
deviat
page
number
citat
purpos
chang
alveolar
dead
space
fraction
nebulis
heparin
dosag
chang
alveolar
dead
space
fraction
nebulis
heparin
dosag
percentag
chang
baselin
alveolar
dead
space
fraction
adsf
mean
standard
deviat
assess
feasibl
safeti
potenti
anticoagul
effect
nebulis
heparin
mechan
ventil
patient
ali
found
administr
nebulis
heparin
mechan
ventil
patient
ali
feasibl
associ
seriou
advers
event
increas
aptt
level
higher
dose
chang
pao
fio
ratio
lung
complianc
alveolar
dead
space
fraction
similar
dose
one
patient
uday
group
blood
stain
respiratori
secret
present
seventh
dose
stain
resolv
follow
withdraw
heparin
found
evid
dosedepend
effect
aptt
tct
level
uday
group
level
remain
within
normal
rang
howev
uday
uday
uday
group
aptt
tct
level
rais
second
day
peak
level
reach
follow
final
nebulis
thereaft
level
fell
uday
group
aptt
reach
therapeut
rang
second
fell
acut
second
follow
cessat
nebulis
heparin
previou
clinic
studi
investig
potenti
system
anticoagul
use
nebulis
heparin
date
without
success
unlik
studi
use
repeat
dose
nebulis
heparin
find
aptt
tct
level
increas
repeat
dose
suggest
pulmonari
process
storag
heparin
endotheli
cell
metabol
heparinas
may
initi
limit
heparin
reach
system
circul
process
may
howev
becom
satur
follow
repeat
heparin
dose
futur
trial
nebulis
heparin
due
consider
must
given
system
anticoagul
effect
also
examin
whether
nebulis
heparin
limit
coagul
increas
fibrinolysi
lung
u
day
group
ptf
level
bal
fluid
doubl
baselin
level
follow
final
nebulis
uday
uday
uday
group
howev
ptf
level
increas
previou
trial
patient
ventilatedassoci
pneumonia
also
found
doubl
coagul
level
bal
fluid
first
day
inconclus
find
rais
possibl
nebulis
heparin
higher
dose
limit
coagul
activ
lung
nebulis
heparin
increas
tpa
level
bal
fluid
dose
studi
one
strength
present
studi
nebulis
system
use
evid
doserel
effect
system
aptt
tct
level
suggest
signific
amount
heparin
reach
alveolar
space
find
consist
previou
studi
anoth
strength
studi
inclus
genuin
highrisk
patient
ali
averag
p
f
ratio
baselin
mmhg
tracheostomi
rate
hospit
mortal
limit
present
studi
includ
absenc
control
group
small
number
patient
enrol
rel
short
time
day
heparin
nebulis
size
studi
reflect
need
caution
nebulis
heparin
previous
administ
patient
ali
furthermor
determin
four
patient
group
would
provid
adequ
power
detect
major
anticoagul
effect
studi
consequ
small
draw
conclus
regard
efficaci
potenti
infrequ
deleteri
effect
previou
studi
anim
model
ali
demonstr
signific
improv
pulmonari
function
inhal
heparin
glycosaminoglycan
heparin
rang
anticoagul
action
also
promot
fibrinolysi
increas
tpa
level
compar
intraven
rout
nebulis
deliv
high
concentr
heparin
alveolar
space
reduc
risk
advers
effect
system
coagul
administr
nebulis
heparin
mechan
ventil
patient
ali
feasibl
heparin
administr
associ
seriou
advers
event
increas
aptt
level
higher
dose
larger
trial
requir
investig
safeti
efficaci
nebulis
heparin
ali
trial
due
consider
must
given
system
anticoagul
effect
page
number
citat
purpos
i
role
studi
design
data
collect
analysi
interpret
data
write
public
manuscript
